Viking Therapeutics, Inc. (VKTX) bonds
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.17−0.71 (-2.64%)
Close on Nov 18, 2026Market cap $3.34BP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Viking Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Viking Therapeutics's 10-Q for the period ended Sep 30, 2026
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| Two Point Zero Zero Convertible Senior Notes Due Two Thousand Thirty Two Convertible at $51 a share | 2.00% | Oct 15, 2032 | $258.80M | $258.75M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?